Ketosis-prone type 2 diabetes with autoantibody negative and beta cell function positive group (KPD) is recognized as atypical diabetes characterized by the onset of disease at a relatively young age, obesity, sudden onset of ketosis and a transient decrease in insulin secretion. Previously we have reported that insulin peptide reactive T cells are detected in KPD patients (2017, ADA meeting). In this study, we examined the correlation between insulin peptide reactive T cells and clinical background such as C-peptide, HbA1c, and HLA types especially focusing on class I region to assess the significance of insulin peptide reactive T cells detected in KPD subjects. Peripheral blood was obtained from enrolled subjects with informed consent, and stimulated with insulin peptides (insulin B9-23, B10-24, B11-25, B12-26) for 24 hours, then interferon (IFN)-gamma spots were counted. Maximum spots more than 2.5 were considered as positive based on the data from control subjects. Seven out of 21 (33.3%) KPD participants (21 males, 0 females, mean age 40.3 years) showed positive result, and this frequency was similar to that in acute-onset type 1 diabetes (17 out of 50; 34.0%) (22 males, 28 females, mean age 44.5 years); these results were consistent with our previous observation. Only 1 out of 35 (2.9%) showed positive result in controls (26 males, 9 females, mean age 61.8 years). In KPD participants, serum C-peptide level was significantly lower in the ELISpot positive group than in the negative group (1.40±0.55 ng/mL vs. 2.35±0.76 ng/mL; p <0.05). Moreover, there was a significant positive correlation between the spot number and HbA1c at onset in the positive group (rs= 0.6232, (p <0.05 by Spearman correlation test). Furthermore, HLA A*02:01 or A*24:02 positive rate was significantly higher in the ELISpot positive group (n=7) than the negative group (n=14) (86% vs. 36%; p <0.05). These findings suggest that insulin peptide reactive IFN-gamma-producing T cells may reflect disease activity of KPD.


A. Satomura: None. S. Suzuki: None. A. Haisa: None. Y. Oikawa: None. A. Shimada: Advisory Panel; Self; Astellas Pharma Inc. Speaker’s Bureau; Self; Eli Lilly Japan K.K., Novo Nordisk Inc., Sanofi-Aventis.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at